NCT00001450View on ClinicalTrials.gov

Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

September 30, 1995

Study Completion Date

June 30, 2000

Conditions
Carcinoma, Non-Small-Cell LungLung Neoplasms
Interventions
DRUG

paclitaxel

DRUG

cisplatin

Trial Locations (1)

20892

National Cancer Institute (NCI), Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00001450 - Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC | Biotech Hunter | Biotech Hunter